A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan

A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan

The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its oral tablet form. Methods: We used the Markov...

Full description

Bibliographic Details
Main Authors: Wan-Ling Ho, Kuo-Piao Chung, Szu-Sheng Yang, Meng-Yao Lu, Shiann-Tarng Jou, Hsiu-Hao Chang, Yung-Li Yang, Dong-Tsamn Lin, Kai-Hsin Lin
Format: Article
Language:English
Published: Elsevier 2013-04-01
Series:Journal of the Formosan Medical Association
Subjects:
cost–utility
deferasirox
quality-adjusted life year
thalassemia
transfusion-dependent
Online Access:http://www.sciencedirect.com/science/article/pii/S0929664612000824

Internet

http://www.sciencedirect.com/science/article/pii/S0929664612000824

Similar Items